KYMERA THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
KYMERA THERAPEUTICS, INC. (KYMR) reported Increase (Decrease) in Prepaid Expense and Other Assets of $3.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$223.00K, a 104.39% decline year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $3.56M.
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $322.00K, a 89.77% decline year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$266.00K, a 107.23% decline year-over-year.
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $2.36M, a 73.48% decline from fiscal 2024.
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $8.90M, a 354.00% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.96M, a 97.68% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $992.00K, a 75.30% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$223.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.34M 10-Q · filed 2026-08-05 | $3.66M derived: sum of 3 quarters · filed 2026-08-05 | $3.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.56M 10-Q · filed 2026-04-30 | $3.89M derived: sum of 2 quarters · filed 2026-04-30 | $3.62M derived: sum of 3 quarters · filed 2026-04-30 | $8.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $322.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $56.00K derived: sum of 2 quarters · filed 2026-02-26 | $5.14M derived: sum of 3 quarters · filed 2026-08-05 | $2.36M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$266.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.82M derived: sum of 2 quarters · filed 2026-08-05 | $2.04M 10-Q · filed 2025-11-04 | $5.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.31M 10-Q · filed 2026-08-05 | $5.45M derived: sum of 3 quarters · filed 2026-08-05 | $9.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.78M 10-Q · filed 2026-04-30 | $373.00K derived: sum of 2 quarters · filed 2026-04-30 | $4.05M derived: sum of 3 quarters · filed 2026-04-30 | $3.12M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.83M derived: sum of 2 quarters · filed 2026-02-26 | $5.90M derived: sum of 3 quarters · filed 2026-02-26 | $8.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.75M derived: sum of 2 quarters · filed 2025-11-04 | $5.75M 10-Q · filed 2025-11-04 | $3.34M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$929.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.08M 10-Q · filed 2025-08-11 | -$341.00K derived: sum of 3 quarters · filed 2026-02-26 | $43.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.00M 10-Q · filed 2025-05-09 | $588.00K derived: sum of 2 quarters · filed 2026-02-26 | $972.00K derived: sum of 3 quarters · filed 2026-02-26 | $3.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.03M derived: sum of 2 quarters · filed 2026-02-26 | $320.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.96M 10-K · filed 2026-02-26 |
| 2023-09-30 | $384.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.74M derived: sum of 2 quarters · filed 2024-10-31 | $4.38M 10-Q · filed 2024-10-31 | $4.86M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $3.99M 10-Q · filed 2024-08-07 | $4.47M derived: sum of 3 quarters · filed 2025-02-27 | $5.62M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.64M 10-Q · filed 2024-05-02 | $2.12M derived: sum of 2 quarters · filed 2025-02-27 | $3.26M derived: sum of 3 quarters · filed 2025-02-27 | $2.05M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $480.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.62M derived: sum of 2 quarters · filed 2025-02-27 | $406.00K derived: sum of 3 quarters · filed 2025-02-27 | $992.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$74.00K derived: sum of 2 quarters · filed 2023-11-02 | $512.00K 10-Q · filed 2023-11-02 | $3.46M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$630.00K 10-Q · filed 2023-08-03 | $2.32M derived: sum of 3 quarters · filed 2024-02-22 | $3.29M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $586.00K 10-Q · filed 2023-05-04 | $3.53M derived: sum of 2 quarters · filed 2024-02-22 | $4.51M derived: sum of 3 quarters · filed 2024-02-22 | $3.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.92M derived: sum of 2 quarters · filed 2024-02-22 | $3.20M derived: sum of 3 quarters · filed 2024-02-22 | $4.02M 10-K · filed 2024-02-22 |
| 2021-09-30 | $977.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $252.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.07M 10-Q · filed 2022-11-03 | $3.44M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$725.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $91.00K 10-Q · filed 2022-08-09 | $2.47M derived: sum of 3 quarters · filed 2023-02-23 | $1.73M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $816.00K 10-Q · filed 2022-05-03 | $3.19M derived: sum of 2 quarters · filed 2023-02-23 | $2.45M derived: sum of 3 quarters · filed 2023-02-23 | $3.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.63M derived: sum of 2 quarters · filed 2023-02-23 | $2.34M derived: sum of 3 quarters · filed 2023-02-23 | $3.82M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$742.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$37.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.44M 10-Q · filed 2021-11-10 | $1.62M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $705.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $2.18M 10-Q · filed 2021-08-06 | $2.36M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $1.48M 10-Q · filed 2021-05-06 | $1.66M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $180.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $564.00K 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $384.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |